New Two-Pronged attack on advanced cancer begins human testing
NCT ID NCT07274813
Summary
This is a first-in-human study to check the safety and side effects of a new experimental drug called HLX37 in people with advanced or spreading solid tumors, including a type of lung cancer (NSCLC). The drug is designed to block two pathways that help tumors grow. The main goal is to find a safe dose and understand how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Air Force Medical University of the People's Liberation Army of China
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.